Evidence map›Paper›PMID 41158460›Full record

ArticleFrontiers in medicine2025

Case Report: Spontaneous pneumomediastinum in a patient with MDA5-positive dermatomyositis and severe pulmonary fibrosis.

M Rizzo, C Braga, M Raschellà, B Maranini, G Schifino, A Carnevale, M Govoni, A Lo Monaco

Abstract readCase Reports
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

M Rizzo *Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy.
C Braga *Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy.
M Raschellà *Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy.
B MaraniniRheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy.
G SchifinoRespiratory Medicine Unit, Department of Cardio-Thoracic-Vascular Pathologies, Arcispedale Sant'Anna, Ferrara, Italy.
A CarnevaleRadiology Unit, Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
M GovoniRheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy.
A Lo MonacoRheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Dermatomyositis (DM) is a rare autoimmune disorder, with the anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody positive subtype associated with severe complications such as rapidly progressive interstitial lung disease (RP-ILD) and, more rarely, spontaneous pneumomediastinum (SPM). This case highlights the challenges of managing a patient with such complex condition, particularly in the context of multiple comorbidities, including a history of cancer and recurrent infections. Case description: A 45-year-old woman with an history of vulvar squamous cell carcinoma (July 2022) presented with classic features of DM, including Gottron's papules, proximal muscle weakness, dysphagia, severe cutaneous vasculitis and lymphopenia. She was then diagnosed with anti-MDA5-positive DM in October 2023. High-resolution CT (HRCT) of the lung performed in January 2024, in the absence of respiratory symptoms, revealed early interstitial changes with ground-glass opacities. Initial corticosteroid therapy yielded partial improvement. A Conclusion: This case emphasizes the complexity of managing anti-MDA5-positive DM with severe pulmonary complications. Early recognition, a multidisciplinary approach, and personalized treatment are crucial to improving outcomes.

Indexed as

anti-MDA5 antibodycase reportdermatomyositispulmonary fibrosisspontaneous pneumomediastinum

Identifiers

PMID41158460
PMCPMC12554667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.